首页 | 本学科首页   官方微博 | 高级检索  
   检索      

尼可地尔联合盐酸曲美他嗪治疗微血管性心绞痛的临床效果和安全性分析
引用本文:张 炜,杨禹娟,孟 航,张小兰,李文波.尼可地尔联合盐酸曲美他嗪治疗微血管性心绞痛的临床效果和安全性分析[J].现代生物医学进展,2018(21):4130-4132.
作者姓名:张 炜  杨禹娟  孟 航  张小兰  李文波
作者单位:陕西省人民医院心内三科 陕西 西安 710068
基金项目:陕西省自然科学基础研究计划项目(2014JM4185)
摘    要:目的:分析尼可地尔联合盐酸曲美他嗪治疗微血管性心绞痛的临床效果和安全性。方法:选择陕西省人民医院2013年1月-2017年1月收治的微血管性心绞痛患者518例为研究对象,根据入院顺序经随机数字表法分为对照组和研究组,对照组260例患者采用盐酸曲美他嗪进行治疗,研究组258例在对照组基础上联合尼可地尔进行治疗,对比两组患者的临床总有效率、内皮血管功能和不良反应发生率。结果:治疗后,研究组的总有效率88.76%(229/258)]显著高于对照组62.69%(163/260)](P0.05);治疗前,两组患者的一氧化氮(NO)、内皮素(ET-1)和C-反应蛋白(CRP)水平均无差异(P0.05);治疗后,两组患者的CRP、ET-1水平均低于治疗前,且研究组低于对照组(P0.05);NO水平均高于治疗前,且研究组高于对照组(P0.05);对照组患者在治疗后的总不良反应发生率为9.23%(24/260),与研究组10.85%(28/258)]相比差异无统计学意义(P0.05)。结论:尼可地尔联合盐酸曲美他嗪较单用盐酸曲美他嗪治疗微血管性心绞痛的效果更好,其可显著改善患者内皮血管功能,且安全性与单用盐酸曲美他嗪相当。

关 键 词:尼可地尔  盐酸曲美他嗪  微血管性心绞痛
收稿时间:2018/4/27 0:00:00
修稿时间:2018/5/23 0:00:00

Analysis of the Efficacy and Safety of Nicorandil Combined with Trimetazidine Hydrochloride in the Treatment of Microvascular Angina
Abstract:ABSTRACT Objective: To analyze the efficacy and safety of nicorandil combined with trimetazidine hydrochloride in the treatment of microvascular angina. Methods: 518 cases of patients with microvascular angina pectoris from January 2013 to January 2017 in Shaanxi Provincial People''s Hospital were selected as the study subjects. According to the admission sequence, they were divided into the control group and the study group by a random number table method, 260 patients in the control group were treated with trimetazidine hydrochloride, and 258 patients in the study group were treated with nicorandil on the basis of control group. The total clinical efficacy, endothelial vascular function and incidence of adverse reactions were compared between the two groups of patients. Results: After treat- ment, the total effective rate of study group was 88.76% (229/258), it was higher than that of the control group62.69% (163/260)](P<0.05); no significant difference was found in the Nitric oxide (NO), endothelin (ET-1), and C-reactive protein (CRP) levels were before treatment between the two groups (P>0.05); after treatment, the CRP and ET-1 levels of both groups of patients were lower than those be- fore treatment, they were lower in the study group than those of the control group(P <0.05); the NO levels of both groups of patients were higher than those before treatment, and it was higher in the study group than that of the control group (P <0.05); the incidence of total ad- verse reactions in the control group after treatment was 9.23% (24/260), and no difference was found in comparison to that of the study group10.85%(28/258)](P> 0.05). Conclusion: Nicorandil combined with trimetazidine hydrochloride had better efficacy in the treatment of microvascular angina pectoris, it can significantly improve the endothelial vascular function of patients with equal safety to trimetazi- dine hydrochloride alone.
Keywords:Nicorandil  Trimetazidine hydrochloride  Microvascular angina
本文献已被 CNKI 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号